<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02359292</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993AB2-01</org_study_id>
    <nct_id>NCT02359292</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers</brief_title>
  <official_title>Cross-over Clinical Pharmacology Study, to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination Across Two Different Dose Strengths, Administered With and Without Activated Charcoal, in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is performed to evaluate the total systemic exposure and lung bioavailability of
      CHF 5993 pMDI combination, in healthy volunteers subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic exposure of B17MP, Formoterol and Glycopyrronium bromide, without charcoal block (To evaluate the total systemic exposure as AUCt and Cmax) Composite outcome measures of PK variables</measure>
    <time_frame>over 32hours after administration</time_frame>
    <description>Composite outcome measures of PK variables</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung exposure of B17MP, Formoterol and Glycopyrronium bromide without charcoal block (To evaluate the lung exposure (as AUCt and Cmax) Composite outcome measures of PK variables</measure>
    <time_frame>over 32hours after administration</time_frame>
    <description>Composite outcome measures of PK variables</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic effects of CHF5993 (To evaluate the systemic effects as potassium and glucose levels) Composite outcome measures of PD variables</measure>
    <time_frame>over 24hours after administration</time_frame>
    <description>Composite outcome measures of PD variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic cardiac effects and the general safety (Composite outcome measures of cardiac variables (such as HR, BP, QT) and safety variables (such as AE, SAE)</measure>
    <time_frame>over 24hours after administration</time_frame>
    <description>Composite outcome measures of cardiac variables (such as HR, BP, QT) and safety variables (such as AE, SAE)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF 5993 HS 200/6/25 pMDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Strength fixed combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5993 MS 100/6/25 pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medium Strength fixed combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5993 HS 200/6/25 pMDI + Charcoal Block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Strength fixed combination plus Charcoal Block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5993 MS 100/6/25 pMDI + Charcoal Block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medium Strength fixed combination plus Charcoal Block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pMDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 HS 200/6/25 pMDI</intervention_name>
    <arm_group_label>CHF 5993 HS 200/6/25 pMDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 MS 100/6/25 pMDI</intervention_name>
    <arm_group_label>CHF 5993 MS 100/6/25 pMDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 HS 200/6/25 pMDI + Charcoal Block</intervention_name>
    <arm_group_label>CHF 5993 HS 200/6/25 pMDI + Charcoal Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 MS 100/6/25 pMDI + Charcoal Block</intervention_name>
    <arm_group_label>CHF 5993 MS 100/6/25 pMDI + Charcoal Block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pMDI</intervention_name>
    <arm_group_label>Placebo pMDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject's written informed consent obtained prior to any study related procedure.

          2. Able to understand the study procedures, the risks involved and ability to be trained
             to use the devices correctly.

          3. Male and female subjects aged 18 to 55 years inclusive.

          4. Body mass index (BMI) within the range of 18 to 30 kg/m2 inclusive.

          5. Non- or ex-smokers who smoked &lt; 5 pack years (pack-years = the number of cigarette
             packs per day, times the number of years) and stopped smoking &gt; 1 year prior to
             screening.

          6. Good physical and mental status, determined on the basis of the medical history and a
             general clinical examination, at screening and before randomization.

          7. Lung function measurements within normal limits (Normal values (according to GINA 2014
             document): FEV1/FVC &gt; 0.70 and FEV1 &gt; 80% predicted).

          8. Male subjects: they and/or their partner must be willing to use an approved method of
             contraception from the time of screening and until 30 days after the last dose of
             study. Subjects must not donate sperm for 30 days after the last dose of study drug.*

          9. Female subjects: post-menopausal women having at least 12 months of natural
             (spontaneous) amenorrhea, or women of childbearing potential (defined as all women
             physiologically capable of becoming pregnant), using an acceptable method of
             contraception

         10. Surgical sterilization (i.e. bilateral tubal ligation, hysterectomy for females;
             vasectomy for males)

         11. Hormonal contraception (implantable, injectable, patch, oral)

         12. Double-barrier methods: condom and occlusive cap (diaphragm or cervical/vault caps)

         13. Placement of an intrauterine device (IUD) or intrauterine system (IUS).

        Exclusion Criteria:

          1. Blood donation (equal or more than 450 ml) or blood loss, less than 8 weeks before
             inhalation of the study medication.

          2. Female subjects: pregnant or lactating women (where pregnancy is defined as the state
             of a female after conception and until the termination of the gestation) confirmed by
             a positive urine test at screening and randomization.

          3. Positive HIV1 or HIV2 serology.

          4. Positive results from the Hepatitis serology which indicates acute or chronic
             Hepatitis B or Hepatitis C.

          5. Unsuitable veins for repeated venipuncture.

          6. History of alcohol abuse within 12 months prior to screening.

          7. History of drug abuse within 12 months prior to screening (or positive urine drug test
             performed at screening).

          8. Subjects who have a positive urine test for cotinine.

          9. Clinically relevant abnormal laboratory values suggesting an unknown disease and
             requiring further clinical investigation. Note: In case of abnormal laboratory values,
             the test can be performed again once before randomization.

         10. Clinically relevant and uncontrolled hepatic, gastrointestinal, endocrine, metabolic,
             neurologic, or psychiatric disorder that may interfere with successful completion of
             this protocol.

         11. History of glaucoma, symptomatic prostatism or urinary retention.

         12. Subjects who have cardiovascular condition such as, but not limited to, unstable
             ischemic heart disease, NYHA Class III/IV left ventricular failure, acute ischemic
             heart disease in the last year prior to study screening, history of sustained cardiac
             arrhythmias or sustained and non-sustained cardiac arrhythmias diagnosed in the last 6
             months (sustained means lasting more than 30 seconds and or ending only with external
             action, and or leads to hemodynamic collapse; non-sustained means &gt; 3 beats &lt; 30
             seconds, and or ending spontaneously, and or asymptomatic), impulse conduction high
             degree blocks, ICD implant

         13. Abnormal ECG (i.e.: QRS &gt; 120 msec, PR &gt; 220 msec, HR &lt; 40 bpm, HR &gt; 110 bpm, QTcF &gt;
             450 ms for males or QTcF &gt; 470 ms for females) at screening.

             Note: In case of abnormal ECG, the test can be performed again once before
             randomization.

         14. Clinically significant abnormal 24h-Holter monitoring at screening (if necessary the
             Holter evaluation can be done on another day before randomization).

         15. Abnormal Blood Pressure (Average Diastolic Blood Pressure &gt; 90 mmHg or average
             Systolic Blood Pressure &gt; 140 mmHg) at screening.

             Note: In case of abnormal blood pressure, measure can be done again once before
             randomization.

         16. Participation in another clinical trial where investigation drug was received less
             than 8 weeks prior to screening.

         17. History of hypersensitivity to any of the excipients contained in the formulations
             used in the trial.

         18. Subject taking any drug treatment, including prescribed or OTC medicines as well as
             vitamins, homeopathic remedies etc, taken in the 14 days before the screening with the
             exception of :

               1. Occasional paracetamol (maximum 2 g per day with a maximum of 10 g per 14 days
                  for mild non-excluding conditions);

               2. Hormonal contraceptives;

               3. Hormonal replacement treatment for post-menopausal women.

         19. Subject taking treatment, with enzyme-inducing or enzyme-inhibiting drugs and biologic
             drugs and with any drug known to have a well-defined potential for hepatotoxicity
             (e.g. isoniazide, nimesulide, ketoconazole), taken since 3 months before screening
             until randomization.

         20. Heavy caffeine drinker (&gt; 5 caffeinated beverages e.g., coffee, tea, cola per day).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SGS CPU Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

